Asset Details
Do you wish to reserve the book?
A retrospective 10 years‐ experience overview of dye laser treatments for vascular pathologies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A retrospective 10 years‐ experience overview of dye laser treatments for vascular pathologies
Do you wish to request the book?
A retrospective 10 years‐ experience overview of dye laser treatments for vascular pathologies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A retrospective 10 years‐ experience overview of dye laser treatments for vascular pathologies
2023
Overview
Introduction The Flash‐lamp pulsed dye laser (FPDL) is nowadays considered the most precise laser currently on the market for treating superficial vascular lesions. In this study, we gathered data from 10 years of experience regarding dye laser treatment of patients presenting vascular malformations such as telangiectasia, rhinophyma, port‐wine stain, cherry and spider angioma and vascular tumours. Methods Subjects were enrolled from 2013 to 2023 based on the vascular anomalies they presented. They underwent different treatment sessions with the FPDL device. Results The age‐range distribution by vascular anomaly confirmed that haemangiomas are typical in children while rhinophyma is a condition very common in older adults. A difference in sex distribution showed that pathologies such as telangiectasias typically affect women whereas rhinophyma is more frequent in men. Most of the treatments interested the face area but no permanent side effects were registered. Conclusions Our 10 years of experience with FPDL demonstrated good results in a wide range of applications for the treatment of different vascular anomalies. The absence of long‐term side effects and bearable pain during the treatment makes it a valuable solution for the resolution of benign tumours also in very young patients.
